TSX runs higher on rate cut expectations
Investing.com - Barclays initiated coverage on Humacyte (NASDAQ:HUMA), currently trading at $1.47 with a market cap of $232 million, with an Overweight rating and a $3.50 price target on Wednesday. According to InvestingPro data, the stock has seen significant volatility, having declined nearly 78% over the past year.
The research firm highlighted Humacyte’s early-stage launch of Symvess in vascular trauma, which represents the first of four initial indications for the company’s acellular tissue engineered vessels (ATEVs). This initial indication addresses challenges in vascular trauma care and represents a potential total addressable market exceeding $600 million. While InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 2.45, it faces challenges with negative profit margins.
Barclays expects commercialization of the second indication in AV access for dialysis in 2027, which could unlock an additional $550 million market opportunity. The firm noted that Humacyte’s platform positions it to pursue further indications including peripheral artery disease and coronary artery bypass graft surgery.
These additional applications represent a combined market opportunity of more than $2 billion, according to Barclays’ estimates. The research firm also pointed to Humacyte’s established manufacturing facility, which produces implantable tissue products using a proprietary bioreactor platform.
Barclays projects that Humacyte’s transition to profitable revenue growth over the next few years will drive significant returns for investors. Analyst targets range from $3 to $25, suggesting significant upside potential. For deeper insights into Humacyte’s financial health and growth prospects, including 13 additional ProTips and comprehensive valuation metrics, check out the full analysis on InvestingPro.
In other recent news, Humacyte reported its second-quarter 2025 earnings, revealing a revenue of $301,000, which fell short of the expected $1.01 million. The company also posted an earnings per share of -$0.24, missing the forecasted -$0.16. Despite these results, Benchmark reiterated its Buy rating with a $14.00 price target, while TD Cowen lowered its price target to $3.50 due to mixed progress in the commercial launch of the Symvess product. H.C. Wainwright also reduced its price target to $3.00, maintaining a Buy rating, citing weak sales. BTIG adjusted its price target to $7.00, noting the mixed second-quarter results. Humacyte’s revenue included $100,000 from Symvess product sales and $201,000 from a research collaboration with an unnamed medical technology company. The company had previously indicated that the majority of its revenue was expected in the second half of the year. Hospital Value Analysis Committee approvals for Symvess increased to 13, up from 5 in the first quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.